Lineage Cell Therapeutics, Inc. Share Price
Equities
LCTX
US53566P1093
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.13 USD | +3.67% | +2.73% | +3.67% |
Sales 2024 * | 17.54M 1.4B | Sales 2025 * | 14.63M 1.17B | Capitalization | 213M 17.03B |
---|---|---|---|---|---|
Net income 2024 * | -21M -1.68B | Net income 2025 * | -25M -2B | EV / Sales 2024 * | 12.2 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 14.6 x |
P/E ratio 2024 * |
-9.97
x | P/E ratio 2025 * |
-9.11
x | Employees | 72 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.87% |
Latest transcript on Lineage Cell Therapeutics, Inc.
1 day | +3.67% | ||
1 week | +2.73% | ||
Current month | +3.67% | ||
1 month | -22.60% | ||
3 months | +30.97% | ||
6 months | +0.89% | ||
Current year | +3.67% |
Managers | Title | Age | Since |
---|---|---|---|
Brian Culley
CEO | Chief Executive Officer | 52 | 16/09/18 |
Jill Howe
DFI | Director of Finance/CFO | 48 | 13/11/22 |
Chief Operating Officer | - | 31/12/09 |
Members of the board | Title | Age | Since |
---|---|---|---|
Neal Bradsher
BRD | Director/Board Member | 58 | 30/06/09 |
Brian Culley
CEO | Chief Executive Officer | 52 | 16/09/18 |
Director/Board Member | 66 | 10/04/14 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.02% | 0 M€ | 0.00% | - | |
0.02% | 0 M€ | 0.00% | - | |
0.00% | 34 M€ | +1.32% | - |
Date | Price | Change | Volume |
---|---|---|---|
01/05/24 | 1.13 | +3.67% | 562,065 |
30/04/24 | 1.09 | -2.68% | 766,968 |
29/04/24 | 1.12 | -1.75% | 428,510 |
26/04/24 | 1.14 | +2.70% | 313,340 |
25/04/24 | 1.11 | +0.91% | 359,695 |
Delayed Quote Nyse, May 01, 2024 at 09:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.67% | 206M | |
+0.67% | 42.19B | |
+44.30% | 40.15B | |
-6.20% | 28.31B | |
+6.55% | 24.63B | |
-21.66% | 18.2B | |
+29.96% | 12.01B | |
-1.57% | 11.76B | |
+16.03% | 10.4B | |
-4.80% | 9.94B |
- Stock Market
- Equities
- LCTX Stock